Sei Investments Co. Increases Holdings in Genmab A/S Sponsored ADR $GMAB

Sei Investments Co. lifted its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 24.1% during the first quarter, HoldingsChannel reports. The firm owned 93,012 shares of the company’s stock after purchasing an additional 18,055 shares during the quarter. Sei Investments Co.’s holdings in Genmab A/S were worth $2,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after acquiring an additional 1,174 shares during the period. Squarepoint Ops LLC boosted its stake in Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after acquiring an additional 81,434 shares during the last quarter. Quantinno Capital Management LP grew its position in shares of Genmab A/S by 64.9% during the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock valued at $3,267,000 after acquiring an additional 62,226 shares during the period. Raymond James Financial Inc. grew its position in shares of Genmab A/S by 48.1% during the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock valued at $643,000 after acquiring an additional 10,113 shares during the period. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Genmab A/S during the 2nd quarter worth approximately $1,172,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Royalty income lifted the outlook. Genmab’s drug-royalty revenue strengthened expectations for the business and was identified as a key reason the stock advanced. Genmab Stock Rises as Drug Royalties Lift Outlook
• Positive Sentiment: Q2 earnings exceeded expectations. Genmab reported EPS of $0.54, topping the $0.37 consensus estimate, while revenue of $1.16 billion surpassed expectations of $1.12 billion. The earnings beat reinforces the company’s profitability and operating momentum. Genmab Quarterly Earnings Results
• Positive Sentiment: Guggenheim raised its price target. The firm increased its target for GMAB from $40 to $42 and assigned a “Buy” rating, implying substantial upside from the stock’s recent trading level. Guggenheim Price Target Report
• Neutral Sentiment: Full-year revenue guidance is broadly in line with analyst expectations. Genmab guided to 2026 revenue of $4.3 billion to $4.5 billion, compared with consensus of approximately $4.4 billion. The range confirms continued growth but does not represent a major consensus reset. Genmab 2026 Q2 Results Presentation

Genmab A/S Price Performance

GMAB opened at $31.25 on Friday. The firm has a 50-day moving average price of $27.31 and a 200-day moving average price of $28.01. Genmab A/S Sponsored ADR has a twelve month low of $21.00 and a twelve month high of $35.43. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $19.49 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 1.96 and a beta of 0.83.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 15.02%. Equities analysts expect that Genmab A/S Sponsored ADR will post 1.11 EPS for the current year.

Analysts Set New Price Targets

GMAB has been the topic of a number of research reports. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their price target for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Truist Financial assumed coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price for the company. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Finally, HC Wainwright upped their price target on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $39.50.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.